TG Therapeutics, Inc. (TGTX): Operating Income
$123.32M
Year ended 2025-12-31
$136.33M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $123.32M | +194.1% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $41.93M | +103.2% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $20.63M | n/m | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | -$218.32M | n/c | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | -$344.77M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$273.59M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$169.06M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$174.40M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$118.71M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$78.97M | n/m | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | -$63.18M | n/m | 2018-03-15, From 2015-01-01 |
| 2014-12-31 | -$55.72M | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | -$22.97M | n/m | 2016-03-15, From 2013-01-01 |
| 2012-12-31 | -$26.90M | n/m | 2014-03-07, From 2012-01-01 |
| 2011-12-31 | -$882.0K | n/a | 2013-03-21, From 2011-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $123.32M | +194.1% |
| Opko Health, Inc. (OPK) | 2025-12-31 | -$117.41M | n/m |
| Insmed Inc (INSM) | 2025-12-31 | -$1.25B | n/m |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | -$166.76M | n/m |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | -$535.00M | n/m |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $44.69M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $77.22M | n/m |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | -$39.16M | n/m |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | -$62.28M | n/m |
Compare TGTX, OPK, INSM, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗